Secondary stroke prevention: inside the vessels and beyond

CNS Drugs
Matthias W Riepe, Roman Huber

Abstract

Cerebral ischaemic stroke is frequently a relapsing, if not chronic, disease. Its incidence is age-dependent, and with the ageing of society the need for effective therapies increases. This review considers current and alternative hypotheses underlying secondary prevention of stroke. Currently, secondary stroke prevention is widely practiced with aspirin (acetylsalicylic acid), a drug that has been in use for more than 100 years. Newer drugs such as ticlopidine and clopidogrel have subsequently been developed, but their efficacy barely surpasses that of aspirin. Other drugs used in secondary stroke prevention include HMG-CoA reductase inhibitors and antihypertensive agents. The endovascular paradigm has shaped the thinking of secondary stroke prevention, and aspirin, ticlopidine and clopidogrel are known as 'platelet inhibitors'; however, their pharmacological and clinical effects are not fully explained within the platelet paradigm. Moreover, in recent years, reduction of stroke incidence has also been observed with HMG-CoA reductase inhibitors, regardless of their lipid-lowering effects. Hence, current understanding needs to be supplemented by considering mechanisms beyond platelet inhibition. Evidence has shown that aspirin,...Continue Reading

References

Sep 24, 1990·Brain Research·K KitagawaK Mikoshiba
Sep 15, 1984·Biochemical Pharmacology·M E Martens, C P Lee
Oct 1, 1995·Stroke; a Journal of Cerebral Circulation·C KosinskiR Töpper
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·C HeurteauxM Lazdunski
Mar 1, 1996·Journal of Clinical Pharmacology·D M GibsonL R Whitfield
Dec 1, 1996·Neuroscience·M A Pérez-PinzónT J Sick
Mar 1, 1997·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M W RiepeJ Hugon
Oct 28, 1997·Stroke; a Journal of Cerebral Circulation·M W RiepeA Raupach
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·M EndresJ K Liao
Dec 23, 1998·Biochemistry and Molecular Biology International·S Sugiyama
Mar 10, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·A Algra, J van Gijn
Jun 4, 1999·Stroke; a Journal of Cerebral Circulation·K KasischkeM W Riepe
Sep 2, 1999·Stroke; a Journal of Cerebral Circulation·M WeihK M Einhäupl
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Mar 21, 2000·The American Journal of Medicine·L KalraD Sulch
Apr 3, 2001·Stroke; a Journal of Cerebral Circulation·S Amin-HanjaniM A Moskowitz
Dec 12, 2001·Stroke; a Journal of Cerebral Circulation·J L WilterdinkM D Hansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Brain Aging

Here is the latest research on intrinsic and extrinsic factors, as well as pathways and mechanisms that underlie aging in the central nervous system.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Cell Aging (Keystone)

This feed focuses on cellular aging with emphasis on the mitochondria, autophagy, and metabolic processes associated with aging and longevity. Here is the latest research on cell aging.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.